Bahija Jallal, Immunocore 🇬🇧 | Commercial, Diversity, and AI | E14

Release Date:

We’re super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a commercial biotech. We also talk about why she thinks gender and race diversity are a business case and how AI is changing protein and biologics engineering.

💎 ABOUT THE SPEAKER
I’ve “known” Bahija for over 10 years, after reading her profile in a student pharma magazine when I was studying bioengineering in France. At that time, she was head of MedImmune and SVP R&D at AstraZeneca. Now as the CEO of Immunocore, with their pioneering T cell receptor platform, she has helped to bring incredible treatments for cancer patients to market.

🔗 LINKS MENTIONED

- Bahija on the Breakthrough Labs podcast - https://open.spotify.com/episode/2X4xedUdJid9GeioRSkCrP?si=39d8c7511aab443f
- Immatics builds on its PRAME Success (and competes with Immunocore) - [OncologyPipeline.com](https://www.oncologypipeline.com/apexonco/immatics-builds-its-prame-success)

📜 TRANSCRIPT
Read the full transcript here:

🫶 FOLLOW US
- Newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://x.com/FlotBio

🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.

⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

⏰ TIMESTAMPS
[00:00:00] Intro
[00:00:34] Welcome
[00:01:46] Immunocore’s life-changing cancer drug
[00:07:40] Commercializing Immunocore
[00:13:46] Explaining the TCR technology
[00:20:40] Targeting tumors with PRAME
[00:23:26] Immunocore now and then
[00:35:37] Why Bahija chose Immunocore
[00:40:22] Top lessons from Bahija Jallal
[00:45:48] How is risk appetite connected to innovation?
[00:49:10] Diversity in biotech
[01:00:59] Biological innovation
[01:05:49] AI in protein engineering optimization
[01:14:42] Thanks for listening

Bahija Jallal, Immunocore 🇬🇧 | Commercial, Diversity, and AI | E14

Title
Flot.bio x Philip Hemme
Copyright
Release Date

flashback